AOD-9604 + CJC-1295 + Ipamorelin Triple Blend
This triple blend combines AOD-9604 (HGH fragment for lipolysis), CJC-1295 No DAC (pulsatile GHRH), and Ipamorelin (selective GHRP) in a single vial. The synergistic combination addresses GH pulsatility, GH-mediated lipolysis, and fat-specific receptor activity simultaneously — studied for body composition research.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL reconstitution)
Concentration after reconstitution: 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin
| Week | Daily Dose | Units (mL) |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3–12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Syringe Math Reference
Using a U-100 insulin syringe (100 units = 1 mL):
- 1 unit (0.01 mL) = 20 mcg AOD + 10 mcg CJC + 10 mcg Ip
- 10 units (0.10 mL) = 200 mcg AOD + 100 mcg CJC + 100 mcg Ip
- 15 units (0.15 mL) = 300 mcg AOD + 150 mcg CJC + 150 mcg Ip
- 20 units (0.20 mL) = 400 mcg AOD + 200 mcg CJC + 200 mcg Ip
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration (maintenance dose: 0.20 mL/day).
| Item | Quantity |
|---|---|
| Peptide Blend Vials (12 mg each) | 8 weeks (~11.2 mL total): 4 vials 12 weeks (~16.8 mL total): 6 vials 16 weeks (~22.4 mL total): 8 vials |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
How This Works
This triple blend leverages three complementary GH-pathway mechanisms. AOD-9604 is fragment 176–191 of HGH — the C-terminal region responsible for HGH's fat-metabolizing activity without IGF-1 stimulation or glucose intolerance. It stimulates lipolysis via β3-adrenergic receptors and inhibits lipogenesis independently of the GH receptor.
CJC-1295 No DAC stimulates the GHRH receptor at the pituitary, amplifying the amplitude of GH pulses. Ipamorelin stimulates ghrelin receptors (GHS-R1a) at both pituitary and hypothalamus, increasing GH pulse frequency and amplitude. Combined, CJC+Ipamorelin produce synergistic GH release while AOD-9604 provides direct fat-specific lipolytic activity downstream.
Potential Benefits & Side Effects
Potential Benefits
- Triple mechanism: GHRH amplification + ghrelin stimulation + direct lipolysis.
- AOD-9604 provides fat-targeted lipolysis without insulin resistance or IGF-1 elevation.
- Fasted state enhances all three components' effectiveness.
- Convenient single-vial formulation vs three separate injections.
- CJC + Ipamorelin synergy well-characterized in secretagogue literature.
Side Effect Profile
- Mild water retention early (GH-mediated).
- Fatigue or morning grogginess if dosed at night.
- Injection-site reactions.
- WADA prohibited — all three components.
- Nausea at higher doses (rare).
- Avoid with active malignancy.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | −20°C, up to 24 months |
| Reconstituted | 2–8°C | Up to 14 days |